The paper analyses venture capitalists' selection process in biotechnology ventures.
INTRODUCTION
All projects that create value find sufficient and adequate financing in perfect financial markets. Real world financial markets, however, are far from perfect. In the presence of market imperfections, investors may ration capital and value creating projects may be denied financing or only be able to obtain certain types of funding 1 . As a special type of new technology ventures, biotechnology companies may find it even harder to get financing 2 . First, biotech -especially biopharmaceutical companies -are characterised by a long development process and the high cash burn rates necessitate large investments 3 .
Biotech is therefore perceived as one of the riskiest industries in our modern economy 4 .
Second, regulatory uncertainty and a negative public opinion may hamper the search for financing 5 . Finally, the biotech technology and product development process are considered to be very complex 6 .
The very nature of venture capital companies (VCs) as financial intermediaries is to reduce information asymmetries and act in uncertain environments 7 . Venture capital is therefore an important source of funding for biotech companies, especially when large investment amounts are needed 8 . In this paper we qualitatively study the biotechnology investment decision process of VCs. The biotech sector is chosen because it is an interesting setting to study the supply of financing under extreme circumstances. Our Third, VCs may require higher hurdle rates for valuation purposes to take into account higher risk or uncertainty. Previous research points out that higher (perceived) technological risk increases the hurdle rate, i.e. the return potential that must be present in a proposal before it is considered as attractive 13, 14 . Finally, VCs may shift risk or uncertainty from the VC to the entrepreneur through contracting. The remainder of the paper is organised as follows. The second section describes the method used in the study and the VC sector in Belgium. Section three gives an overview of the typical characteristics of a biotech investment proposal from the perspective of a VC. Section four describes how VCs deal with the distinctive biotech characteristics in their selection process. Finally, section five concludes and offers avenues for future research. We end with propositions that can be more formally tested in the future.
METHOD AND RESEARCH SETTING
Given the lack of in-depth insight in the selection process of biotech proposals, we opt for a qualitative research design. Data are collected through semi-structured interviews and questionnaires. Both interview guide and questionnaire are pre-tested with two sector specialists. We use interviews as a data collection method for several reasons. First, our pre-test indicated that VCs are not always willing to return comprehensive mail surveys but prefer face-to-face interviews. It is often necessary to establish a relationship with the venture capital manager before receiving a response 20 . Second, research based solely on mail questionnaires may fail to obtain the full essence of a VC's investment process 21 . It is, for example, difficult to get comprehensive answers on unprompted questions 22 . We supplement the interviews with a structured questionnaire, which includes both hard data on, for example, fund characteristics and investment criteria and Likert scales. We carefully select fund managers or senior investment managers for the interviews. They all have relevant experience in venture capital and more specifically in biotech investments. The interviewees were first contacted by phone; we additionally asked to prepare a questionnaire before the interview. If interviewees did not complete the questionnaire before the interview, we asked them to complete the questionnaire at the end of the interview.
During the interview, the two interviewers follow a guideline to minimise interviewer effects. The interviews last between one hour and a half and two hours. All interviews are transcribed verbatim. To ensure validity of the transcription process, the interviews are taped and one of the interviewers takes notes. Next to the interview, we collect data from the written questionnaires. 
VENTURE CAPITALISTS' PERCEPTIONS OF THE SPECIFIC BIOTECH CHARACTERISTICS
Biotech is perceived to be one of the riskiest industries in our modern economy 28 .
This is explained by the main characteristics of biotech companies. First, biotech is characterised by a lengthy process to develop a technology into a market ready product, especially in the drug development segment. The whole process from the discovery phase to a market ready product takes on average 15 years 29 . The long path to a market ready product has several consequences. First, biotech companies are confronted with high failure probabilities. In the biopharmaceutical sector, for example, only one out of 5,000
compounds that emerge from pre-clinical testing is introduced on the market 30 Finally, due to the long path to a market ready product in biotech, there is huge uncertainty about the potential exit route. Three interviewees explicitly mention higher uncertainty on a potential exit as a risk factor for biotech. A generalist investor states exit routes are often discussed before investing in an ICT company, while this is not possible in biotech.
Next to the long path from technology to a market ready product, other risk factors are mentioned by the interviewees, for example regulatory issues. European biotech companies have to pass higher hurdles compared to their American counterparts because of regulatory fragmentation between countries. A biotech specialist highlights that the drug approval and reimbursements systems are still fragmented in the European Union.
Further, a negative public opinion will usually not directly influence VCs' investment decisions, but may influence their decision indirectly through its impact on governments and consequently on regulation. Understanding the technology and product development may present an extra difficulty, especially for generalist investors, but also for specialists.
In summary, biotech investors identify three distinctive characteristics of biotech companies, namely a long path to a market ready product, regulatory difficulties and a technology which is difficult to understand. In the next section we discuss the impact of these distinctive characteristics on VCs' selection process.
VENTURE CAPITAL COMPANIES' SELECTION PROCESS
When discussing the VCs' selection process for biotech proposals, the results are 
Investment strategy and initial screening
One of the most radical ways to deal with the high risk environment is to exclude specific biotech proposals. This can either be based on the specific biotech segment, on the stage of development of the venture or on the VCs portfolio strategy.
Ten VCs in our sample reject proposals from certain biotech segments without further scrutiny. First, because of the unclear regulatory environment and negative public Specialised VCs, however, not solely rely on their internal investment managers. It is interesting to note that the importance of external validation is stressed even by VCs which are considered to be the leading Belgian specialists in biotech investments by their peers. Even the investment decision of highly specialised VCs is taking external information and validation into account. For example, some specialist investors mention that they are more keen to invest in a biotech company which has a strategic alliance, because it offers an external validation of the technology. This implies that internal and external information and validation are complements, rather than substitutes.
Criteria
Based on unprompted answers from the VCs we find that -in order of importancefinancial elements, market, technology and entrepreneurial management team are the most important criteria within the due diligence phase of biotech companies. Our research leads to categories of investment criteria, which are consistent with previous research. We report, however, some differences in the relative importance of the different categories First, nine VCs mention financial elements as the most important requirement of a business plan. VCs require a business plan with a complete financial plan based on realistic assumptions. This is somewhat inconsistent with VCs assertion that it is extremely difficult to forecast the future of a biotech venture, given technological and market uncertainties. VCs nevertheless require biotech entrepreneurs to seriously consider these financial elements.
VCs look beyond the current financing round: they anticipate follow-on financing and even require that sufficient funding is guaranteed to develop a venture before they invest in it. This, again, puts a strong burden on the venture, as it may lead to a chickenand-egg problem. Early stage VCs require that the full investment cycle is laid out, while later stage VCs only want to commit themselves when the technology and market have been proven. As one interviewee stated:
"There is a risk that investors underestimate the amount of funds needed to develop the business. In that case, they get stuck somewhere in the middle of the process of creating a valuable business. This is a very important risk for us and this risk is more important for biotech compared to other businesses." (Early and later stage generalist)
VCs further clearly fear dilution in subsequent financing rounds. This can largely be explained by the large financing needs of biotech companies. consequently reduce at least partially the uncertainty surrounding the technology.
Intellectual property rights are further a requirement to be able to realise an appropriate return, although they offer no guarantee for success. 
Valuation
A critical element in the negotiation process between the VC and the entrepreneur Given the lack of a standard valuation tool, the difficulty to assess the future in a biotech setting and the VCs' reliance on qualitative measures, it is not surprising that the most important reason why negotiations break down is disagreement concerning the value of the proposal. Ten interviewees mention they failed to close a deal due to disagree on valuation on at least one occasion in the previous three years. Furthermore, differences in risk perception between VCs and entrepreneurs make it even more difficult to agree on valuation. All VCs agree there are important differences in risk perception: entrepreneurs underestimate the risks. This was expressed by one interviewee as follows:
"When the technology is validated, a lot of entrepreneurs assume they reached the finish. What they do not realise is that the story here only begins." (Early and later stage biotech specialist)
VCs attribute this difference in risk perception to entrepreneurs who are emotionally bounded to the project and underestimate risks in their enthusiasm, while VCs are experienced and therefore more realistic. VCs have seen numerous entrepreneurs, who are certain their invention will be extremely successful, but who eventually fail to become star performers. According to six interviewees, differences in risk perception are even stronger for biotech entrepreneurs than for other technology-based entrepreneurs. VCs attribute this greater difference to the long development path to turn technology into a market ready product and more specifically the larger financing needs and higher risks because of this lengthy process.
Contracting
A well-documented way to reduce agency risk is to use extensive contracts 50,51 .
Given the high risk environment, we expect that biotech investors write more extensive contracts, as this restricts the entrepreneur from taking actions to the detriment of the principal, in this case the VC. However, we find no evidence that VCs require more The results from the Likert scales are consistent with the information collected from the interviews. Agency risk is neither mentioned directly nor indirectly by the majority of VCs interviewed. This indicates that agency risk is not necessarily (perceived to be) higher in biotech, but that uncertainty for both the VC and entrepreneur plays a more dominant role. In highly volatile, high R&D-intensive industries, where the actual outcome of a business is not necessarily determined by management commitment and competence, shifting risk beyond the control of the entrepreneurs from investors to entrepreneurs will be deemed as unfair and will therefore be expensive from the VCs' point of view. Our results are in line with incomplete contract theory, which states that incomplete contracts are negotiated because of uncertainty and more attention is paid to active involvement in the investment ex-post 54 .
CONCLUSION
Previous research on UK VCs has shown that VCs use stricter selection criteria for technology-based companies compared to non-technology-based companies. We focus on how the typical characteristics of biotech companies influence the selection process of Belgian VCs. The biotech setting is chosen because it represents an interesting setting to study the supply of financing under extreme circumstances. There is a long development path to turn a technology into a market ready product, there are issues of regulatory uncertainty, negative public opinion and difficulty to understand the technology and product development. These are distinctive characteristics of biotech ventures. Table 2 summarises the main findings of our study. The VCs' investment decision process usually starts with a rough screening to examine whether the proposal meets the VCs' investment strategy. The most radical way in which VCs deal with the particularities of biotech companies is to define an investment strategy that excludes certain biotech segments or investment stages, in order to reduce the risk or uncertainty inherent to biotech.
Proposals that fit the investment strategy and pass the screening phase are examined in more detail during the due diligence process. VCs combine information from the business plan with internal knowledge and information from external sources. They are at a competitive disadvantage compared to their American competitors. These barriers should therefore be removed. Further, increasing the investor readiness of entrepreneurs, especially with respect to market development and financial issues, is badly needed. Educational and support services could be set up to assist in these areas.
FIGURE 1
The selection process of a venture capital investment * * Our study focuses on the VCs activities after deal generation and before the actual investment. 
